NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 12 May 2022, 09:00am

**Location:** Zoom Conference Call

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Laura Bojke Present for all items
4. Professor Iolo Doull Present for all items
5. Dr James Fotheringham Present for all items
6. Dr Mark Glover Present for all items
7. Professor Nicholas Latimer Present for items 4 – 5.3.2
8. Professor David McAllister Present for all items
9. Dr Rhiannon Owen Present for all items
10. Anna Pracz Present for all items
11. Gabriel Rogers  Present for all items
12. Dr Toby Smith Present for all items
13. Mary Weatherstone Present for all items
14. Professor Nicky Welton Present for all items
15. Nigel Westwood Present for all items
16. Peter Wheatley-Price Present for all items
17. Dr Stuart Williams Present for all items
18. Tony Wootton Present for all items

NICE staff present

Sam Roberts, Executive Director Present for items 1 - 2

Henry Edwards, Associate Director Present for all items

Richard Diaz, Associate Director Present for all items

Jeremy Powell, Project Manager Present for all items

Natalie Spray, Programme Manager, TA, Planning and Ops Present for items 1 - 3

Rufaro Kausi, HTA Adviser Present for items 1 - 4.3.2

Stephen Norton, HTA Analyst Present for items 1 – 4.3.2

Philip Williams, Business Analyst, RIA Present for items 1 – 4.1.3, 5 – 5.1.3 & 5.3 – 5.3.2

Adam Brooke, Technical Adviser Present for items 5 - 5.3.2

Neha Jiandani, Technical Analyst Present for items 5 – 5.3.2

Susan O’Connell, Technical Analyst Present for items 1 – 4.3.2

Ying-Ying Wang, Technical Analyst Present for items 5 – 5.3.2

Helen Barnett, Senior Medical Editor Present for items 1 – 4.1.3

Anna Sparshatt, Senior Medical Editor Present for items 1 – 4.3.2

Ann Richardson, Communications Manager Present for items 1 – 4.1.3

Catherine Pank, Assistant Project Manager, COT Present for items 5 – 5.3.2

Laura Marsden, Adviser, PiP Present for items 1 – 4.1.3

Lyn Davies, Coordinator, MiP Present for items 1 – 4.1.3 & 5 – 5.1.3

Rosalee Mason, Coordinator, MiP Present for items 5 – 5.1.3

Rumana Zuman, Administrator, TA Present for items 1 – 4.3.2

Laura Kelly, Administrator, COT Present for all items

External assessment group representatives present

Tracey Jhita, BMJ Present for items 1 – 4.2.1

Charlotta Karner, BMJ Present for items 1 – 4.2.1

Gemma Marceniuk, BMJ Present for items 5 – 5.2.1

Charlotta Karner, BMJ Present for items 5 – 5.2.1

Clinical, Patient & NHS England experts present

Dr Natalie Charnley, Consultant Oncologist, Kidney Care UK. Present for items 1 – 4.1.3

Dr Peter Clark, Cancer Drugs Fund Lead, NHS England. Present for items 1 – 4.3.2

Professor Thomas Powles, Professor of Genitourinary Oncology, Director of Barts Cancer Centre & Lead for Solid Tumour Research, St Bartholomew's Hospital nominated by MSD. Present for items 1 – 4.1.3

Dr Jane Ravenscroft, Consultant Dermatologist, nominated by the British Association of Dermatologists. Present for items 5 – 5.1.3

Ms Sophie-Ann Scott, Nurse, Kidney Cancer UK. Present for items 1 – 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Carlo Berti, Ms Denise Bryceland & Dr Veline L’Esperance.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 14 April 2022

### Appraisal of Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from MSD (Merck Sharp & Dohme (UK) Limited.)
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Nick Latimer declared a non-financial professional and personal interest, as of October 2021, he has been a member of the ScHARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme. This is not drug or appraisal specific and is about developing methods. Merck, Sharpe and Dohme are the manufacturer. This declaration was read to the committee by the chair - Dr Charles Crawley - and it was agreed that this declaration would not prevent Professor Latimer from taking part in this discussion.
* Sophie-Ann Scott declared an indirect financial interest has her organisation - Kidney cancer UK - has received funding from Pfizer Merck and BMS for various projects. It was agreed that this declaration would not prevent Sophie-Ann Scott from providing expert advice during this discussion.
* Dr Natalie Charnley declared a direct financial interest as she has received meeting sponsorship from BMS, Ipsen and Eusa, and speaker fees from Pfizer and Ipsen. Dr Charnley also declared a direct non-financial interest, having received research sponsorship from BMS, and an indirect financial interest as her organisation (Kidney Cancer UK) has received funding from BMS, Merck and Pfizer. It was agreed that these declarations would not prevent Dr Charnley from providing expert advice in this discussion
* Professor Thomas Powles declared a direct financial interest as he has been renumeration by MSD for his work on advisory boards, and furthermore declared indirect financial interests having sat on advisory/research boards (honorarium) for the following pharmaceutical companies: AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Roche. Professor Powles has also received travel/accommodation expenses from the following pharmaceutical companies: Roche, Pfizer, MSD, AstraZeneca, Ipsen, and his institution has received grants/funding from AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai. Professor Powles declared a direct non-financial interest as he has received academic credit for satellite symposia, co-leading the pembrolizumab study and leading on a number of trials for MSD. It was agreed that these declarations would not prevent Professor Powles from providing expert advice during this discussion.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Henry Edwards (Clinical), Professor Nicky Welton (Cost) and Tony Wootton (Lay).
	1. Part 2a – Closed session (members of the public and clinical and patient experts were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10693>

### Appraisal of Upadacitinib, abrocitinib and tralokinumab for dermatitis [ID3960]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Abbvie, LeoPharma & Pfizer.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr James Fotheringham declare a direct financial interest as he received advisory board honorarium in July 2021, paid to him directly by Novartis (comparator company.) The subject for this advisory board was Solid Organ Transplantation. It was agreed that this declaration would not prevent Dr Fotheringham from attending this discussion.
* Professor Nick Latimer declared a non-financial professional interest as he is a member of the ScHARR team for a consultancy project (May-October 2021) involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are listed as a comparator company who is not participating. It was agreed that this declaration would not prevent Professor Latimer from attending this discussion.
* Professor David McAllister declared a non-financial professional and personal interest as a co-author on a Pfizer led publication concerning anticoagulation for atrial fibrillation, which is currently under submission for peer review. It was agreed that this declaration would not prevent Professor McAllister from being present for this discussion.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.This information was presented to the committee by the chair, Dr Charles Crawley.
	1. Part 2a – Closed session (company representatives, clinical experts and members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members..
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10856>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 9 June 2022 and will start promptly at 09:30am.